We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

95 hedge funds and large institutions have $39.7M invested in Relmada Therapeutics in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 35 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 14

4% more funds holding

Funds holding: 91 → 95 (+4)

2% less capital invested

Capital invested by funds: $40.3M → $39.7M (-$652K)

5.6% less ownership

Funds ownership: 59.11% → 53.52% (-5.6%)

34% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 35

81% less call options, than puts

Call options by funds: $271K | Put options by funds: $1.4M

Holders
95
Holders Change
+4
Holders Change %
+4.4%
% of All Funds
1.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
23
Reduced
35
Closed
14
Calls
$271K
Puts
$1.4M
Net Calls
-$1.13M
Net Calls Change
-$1.28M

Top Buyers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
+$578K
2
Bank of America
Bank of America
North Carolina
+$552K
3
RC
RBF Capital
California
+$537K
4
PAI
Palo Alto Investors
California
+$526K
5
PCM
Parsons Capital Management
Rhode Island
+$418K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$3.41M
2
State Street
State Street
Massachusetts
-$1.17M
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$741K
4
Walleye Capital
Walleye Capital
New York
-$593K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$539K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
26
Citigroup
New York
$294K +$330K +119,318 New
Federated Hermes
27
Federated Hermes
Pennsylvania
$281K +$315K +114,124 New
AI
28
AdvisorShares Investments
Maryland
$278K +$24.2K +8,758 +8%
GIM
29
Guild Investment Management
California
$274K +$21.1K +7,650 +7%
Connor, Clark & Lunn Investment Management (CC&L)
30
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$257K -$15.1K -5,444 -5%
MOS
31
MGO One Seven
Ohio
$246K +$276K +100,000 New
UBS Group
32
UBS Group
Switzerland
$244K +$269K +97,410 +6,173%
AW
33
Apricus Wealth
South Carolina
$220K – – –
Fidelity Investments
34
Fidelity Investments
Massachusetts
$208K -$13.6K -4,929 -6%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$195K -$205K -74,075 -48%
Squarepoint
36
Squarepoint
New York
$194K +$218K +79,020 New
BCM
37
Bridgeway Capital Management
Texas
$191K +$124K +45,000 +138%
Dimensional Fund Advisors
38
Dimensional Fund Advisors
Texas
$184K +$53K +19,185 +35%
IC
39
Ikarian Capital
Texas
$161K – – –
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$151K -$46.5K -16,812 -22%
Northern Trust
41
Northern Trust
Illinois
$117K -$449K -162,541 -77%
Qube Research & Technologies (QRT)
42
Qube Research & Technologies (QRT)
United Kingdom
$112K +$126K +45,529 New
OMC
43
Old Mission Capital
Illinois
$111K +$125K +45,099 New
Simplex Trading
44
Simplex Trading
Illinois
$109K +$110K +39,859 +885%
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
$105K -$3.44K -1,245 -3%
YIH
46
Y-Intercept (HK)
Hong Kong
$105K +$118K +42,574 New
SEI Investments
47
SEI Investments
Pennsylvania
$89.1K -$2.04K -739 -2%
Verition Fund Management
48
Verition Fund Management
Connecticut
$85.4K +$95.9K +34,700 New
MHC
49
Meyer Handelman Company
New York
$80.1K – – –
PP
50
PDT Partners
New York
$78.1K -$104K -37,621 -54%
1
2
3 4 5

RLMD Hedge Fund Activity: Q2 2023 in Review

95 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q2 2023, worth a combined $39.7M — down 1.6% from $40.3M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new RLMD positions and 14 closed out — a net gain of 4 holders — while 23 added to existing stakes and 35 trimmed.

The largest buyer was GSA Capital Partners, adding an estimated $578K. The largest seller was BlackRock, cutting an estimated $3.41M.

  • 95 institutional investors held Relmada Therapeutics (RLMD) as of Q2 2023, up from 91 in Q1 2023.
  • Funds reported $39.7M of Relmada Therapeutics stock for Q2 2023, down 1.6% quarter-over-quarter.
  • 18 funds opened new Relmada Therapeutics positions in Q2 2023 and 14 closed out, a net change of +4 holders.
  • The largest Relmada Therapeutics buyer in Q2 2023 was GSA Capital Partners, an estimated $578K added.
  • The largest Relmada Therapeutics seller in Q2 2023 was BlackRock, an estimated $3.41M sold.

Based on aggregated 13F filings for Q2 2023.